Quantumzyme to Participate in BioLogic Summit 2026, Highlighting AI's Role in Sustainable Pharmaceutical Manufacturing

Quantumzyme Corp., a biotransformation company focused on sustainable pharmaceutical manufacturing, announced its participation in the second annual BioLogic Summit scheduled for January 19-22, 2026, in San Diego. The summit represents a premier gathering for professionals exploring machine learning and artificial intelligence applications in biotherapeutics design and optimization.

The company's attendance underscores its strategic focus on remaining engaged with advancements in AI-enabled enzyme engineering and protein design. This involvement comes as Quantumzyme pursues its proposed strategic evolution to Quantum Genesis AI Corp., pending FINRA approval. The conference provides a platform for the company's scientific leadership to participate in technical discussions, share insights with peers, and explore emerging advancements aligned with its internal development efforts.

The BioLogic Summit specifically caters to hybrid scientists who integrate experimental and computational methods, a profile matching the expertise of the Quantumzyme team. By attending, the company aims to stay informed about the latest developments in generative AI, lab-in-the-loop optimization, and structure-based design approaches. These insights are intended to support the continued advancement of the company's platform and ensure alignment with the most relevant methodologies in the field.

"Innovation doesn't happen in isolation. Being present and actively engaging with the brightest minds in our field is essential to driving our mission forward," stated Naveen Kulkarni, CEO of Quantumzyme Corp. "The BioLogic Summit provides a valuable venue for our team to connect with individuals and organizations who are contributing to the future of AI in biologics."

The company's goal is to learn from the latest research, better understand emerging challenges, and explore potential collaborations that may support the adoption of greener and more efficient manufacturing approaches across the pharmaceutical industry. For more information, visit www.quantumzymecorp.com and the company's profile at www.otcmarkets.com/stock/QTZM.

This development matters because it highlights the growing intersection of artificial intelligence and sustainable pharmaceutical manufacturing. As the industry faces increasing pressure to reduce environmental impact while maintaining efficiency, companies like Quantumzyme are positioning themselves at the forefront of computational solutions. Their participation in specialized conferences like the BioLogic Summit demonstrates how industry leaders are actively seeking collaborative approaches to address complex manufacturing challenges through technological innovation.

The implications extend beyond corporate strategy to broader industry transformation. As AI-driven enzyme engineering advances, pharmaceutical manufacturers may achieve significant reductions in waste, energy consumption, and production costs while maintaining therapeutic efficacy. This represents a critical step toward more sustainable healthcare systems worldwide, potentially lowering drug development costs and environmental footprints simultaneously.